Oncologist-Reported Barriers and Facilitators to Offering Cancer Clinical Trials to Their Patients

Author:

Castillo Brenda S.1,Boehmer Leigh2,Schrag Janelle3,Howson Alexandra4ORCID,Oyer Randall5ORCID,Pierce Lori6,Barrett Nadine J.7,Guerra Carmen E.189ORCID

Affiliation:

1. Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

2. Association of Community Cancer Centers, Rockville, MD 20850, USA

3. Whitman-Walker Institute, Washington, DC 20009, USA

4. Thistle Editorial LLC., Snoqualmie, WA 98065, USA

5. Ann B. Barshinger Cancer Institute, Penn Medicine Lancaster General Health, Lancaster, PA 17601, USA

6. Rogel Comprehensive Cancer Center at the University of Michigan, Ann Arbor, MI 48109, USA

7. Duke Clinical and Translational Science Institute and Duke Cancer Institute, Durham, NC 27701, USA

8. Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA

9. Leonard Davis Institute, University of Pennsylvania, Philadelphia, PA 19104, USA

Abstract

NCCN guidelines indicate that cancer clinical trials (CCTs) are the best management for patients with cancer. However, only 5% of patients enroll in them. We examined oncologists’ perceived barriers and facilitators to discussing CCTs. This qualitative study was part of the ASCO-ACCC Initiative to Increase Racial and Ethnic Diversity in Clinical Trials. Barriers and facilitators at the system, trial, provider, and patient levels were examined. To achieve triangulation, patient encounters were reviewed using chart-stimulated recall (CSR) methods, thereby obtaining a valid assessment of physician performance. Ten oncology providers participated in this study. Nine were oncologists, and one was a clinical research coordinator; five were female; four were White; three were Asian; and three were Black. Barriers to offering CCTs were a lack of trial availability; ineligibility; a lack of knowledge; assumptions about patient interest, benefits, or harms; patient’s disease factors; and negative attitudes. Facilitators of offering CCTs were a physical space to discuss trials; greater trial availability; a systematic approach to offering trials; patient factors; patients seeking trials; a lack of comorbidities; patients being younger in age; patients being aware of, asking about, or hearing of trials from their surgeon; and higher levels of altruism. Many of the cited barriers are addressable with the cited facilitators. A larger study is needed to generalize and validate these findings.

Funder

Conquer Cancer Foundation

ASCO Foundation

Publisher

MDPI AG

Reference28 articles.

1. NCCN (2023, September 01). Policy Priority: Ensure Patient Accessibility to Guideline-Supported Care. Available online: https://www.nccn.org/business-policy/policy-and-advocacy-program/policy-priorities/policy-priority-access.

2. Institute of Medicine of the National Academics (2010). The National Academies Collection: Reports Funded by National Institutes of Health. Transforming Clinical Research in the United States: Challenges and Opportunities: Workshop Summary, National Academies Press.

3. Participation in cancer clinical trials: Race-, sex-, and age-based disparities;Murthy;JAMA,2004

4. Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation;Unger;J. Natl. Cancer Inst.,2019

5. Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials;Tejeda;J. Natl. Cancer Inst.,1996

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3